Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
98.59(c) 98.42(c) 100.52(c) 101.79(c) 102.27(c) Last
577 765 591 896 1 452 458 889 828 699 307 Volume
+0.72% -0.17% +2.13% +1.26% +0.47% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 131 M - -
Net income 2021 230 M - -
Net cash position 2021 725 M - -
P/E ratio 2021 44,3x
Yield 2021 -
Sales 2022 1 430 M - -
Net income 2022 416 M - -
Net cash position 2022 1 589 M - -
P/E ratio 2022 24,9x
Yield 2022 -
Capitalization 9 669 M 9 669 M -
EV / Sales 2021 7,91x
EV / Sales 2022 5,65x
Nbr of Employees 865
Free-Float 97,7%
More Financials
Company
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA... 
More about the company
Ratings of Neurocrine Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about NEUROCRINE BIOSCIENCES, INC.
06/15NEUROCRINE BIOSCIENCESá : Insider Makes Significant Stock Sells in Neurocrine Bi..
MT
06/14INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Neurocrine Biosciences
MT
06/01NEUROCRINE BIOSCIENCESá : to Present at the Goldman Sachs 42nd Annual Global Hea..
PR
05/21NEUROCRINE BIOSCIENCES INCá : Submission of Matters to a Vote of Security Holder..
AQ
05/17POLYCYSTIC OVARY SYNDROME PIPELINE : Emerging Therapies and Key pharma players i..
AQ
05/11NEUROCRINE BIOSCIENCESá : to Present at the 2021 RBC Global Healthcare Conferenc..
PR
05/10NEUROCRINE BIOSCIENCESá : Cantor Fitzgerald Adjusts Price Target on Neurocrine B..
MT
05/06NEUROCRINE BIOSCIENCESá : JPMorgan Adjusts Price Target for Neurocrine Bioscienc..
MT
05/06CORRECTION : Goldman Sachs Adjusts Price Target for Neurocrine Biosciences to $1..
MT
05/06NEUROCRINE BIOSCIENCESá : Goldman Sachs Adjusts Price Target for Neurocrine Bios..
MT
05/06NEUROCRINE BIOSCIENCESá : Mizuho Adjusts Price Target on Neurocrine Biosciences ..
MT
05/06NEUROCRINE BIOSCIENCESá : Oppenheimer Adjusts Neurocrine Biosciences PT to $140 ..
MT
05/06NEUROCRINE BIOSCIENCESá : Barclays Upgrades Neurocrine Biosciences to Overweight..
MT
05/06NEUROCRINE BIOSCIENCESá : SVB Leerink Adjusts Price Target on Neurocrine Bioscie..
MT
05/06NEUROCRINE BIOSCIENCESá : Morgan Stanley Adjusts Price Target on Neurocrine Bios..
MT
More news
News in other languages on NEUROCRINE BIOSCIENCES, INC.
04/22Idorsia a réduit ses pertes au 1er trimestre
04/22Idorsia a réduit sa perte au 1er trimestre
04/22Idorsia schliesst erstes Quartal 2021 besser als erwartet ab
04/22GlobeNewswire/Idorsia gibt Finanzergebnisse für -3-
04/22GlobeNewswire/Idorsia gibt Finanzergebnisse für das erste Quartal 2021 bekann..
More news
Analyst Recommendations on NEUROCRINE BIOSCIENCES, INC.
More recommendations
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 102,27 $
Average target price 122,54 $
Spread / Average Target 19,8%
EPS Revisions
Managers and Directors
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
Matthew C. Abernethy Chief Financial Officer
William H. Rastetter Chairman
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.6.70%9 669
GILEAD SCIENCES, INC.15.09%84 093
WUXI APPTEC CO., LTD.35.27%68 536
BIONTECH SE190.10%57 117
REGENERON PHARMACEUTICALS10.54%55 301
VERTEX PHARMACEUTICALS-20.09%48 892